KDR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: First-line ICI + VEGFR-TKI combinations are increasingly favored for metastatic tRCC in eligible patients, while optimal management of <i>TFEB</i>-amplified RCC remains uncertain.